Connect your AI

TTRX TTRX Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Regeneron PharmaceuticalsREGN

——

PTH

Pelthos Therapeutics Inc.PTHS

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

Operating cash flow-$1.6M-448%

Valuation

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TTRX's contract liabilities, non-current?: TTRX (TTRX) reported contract liabilities, non-current of $1.44M in Q1 2026.